| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 77.90 | -27 |
| Intrinsic value (DCF) | 49.06 | -54 |
| Graham-Dodd Method | 13.20 | -88 |
| Graham Formula | 14.60 | -86 |
Revvity, Inc. (formerly PerkinElmer) is a global leader in diagnostics, life sciences, and applied services, serving pharmaceutical, biotechnology, academic, and healthcare sectors. Headquartered in Waltham, Massachusetts, Revvity operates through two key segments: Discovery & Analytical Solutions and Diagnostics. The company provides cutting-edge instruments, reagents, software, and services that drive breakthroughs in genomics, oncology, infectious disease testing, and environmental health. With a strong presence in life sciences research, Revvity supports drug discovery, genetic disorder screening, and industrial analytical solutions. Its diversified portfolio caters to laboratories, research institutions, and healthcare providers, positioning it as a critical player in precision medicine and diagnostics. The company’s rebranding in 2023 reflects its focus on innovation and growth in high-potential healthcare markets.
Revvity presents a compelling investment case with its diversified portfolio in high-growth diagnostics and life sciences markets. The company’s strong revenue base ($2.76B in FY 2024) and solid operating cash flow ($628M) underscore financial stability. However, its high total debt ($3.3B) and modest net income ($270M) suggest leverage risks. The stock’s beta of 1.02 indicates market-aligned volatility, while a dividend yield (~0.28/share) offers modest income. Investors should weigh Revvity’s innovation-driven growth in genomics and diagnostics against competitive pressures and debt levels.
Revvity competes in the diagnostics and life sciences tools sector, where differentiation hinges on technological innovation and global reach. Its Discovery & Analytical Solutions segment competes with firms like Thermo Fisher and Agilent, leveraging a broad portfolio of instruments and informatics. The Diagnostics segment faces rivalry from Quest Diagnostics and Bio-Rad, particularly in genetic and infectious disease testing. Revvity’s competitive edge lies in its integrated solutions, spanning research to clinical diagnostics, and its strong R&D focus. However, larger competitors like Thermo Fisher benefit from greater scale and diversified revenue streams, while niche players may outpace Revvity in specialized areas. The company’s rebranding signals a strategic shift toward high-growth areas like precision medicine, but execution risks remain in a crowded market.